Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2

BACKGROUND. We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and/or tumor biomarkers in melanoma patients at high risk for recurrence. METHODS. Patients we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yang, Richard K., Kuznetsov, Igor B., Ranheim, Erik A., Wei, Jun S., Sindiri, Sivasish, Gryder, Berkley, Gangalapudi, Vineela, Song, Young K., Patel, Viharkumar, Hank, Jacquelyn A., Zuleger, Cindy, Erbe, Amy K., Morris, Zachary S., Quale, Renae, Kim, KyungMann, Albertini, Mark R., Khan, Javed, Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334053/
https://ncbi.nlm.nih.gov/pubmed/32152202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados